Pipeline

Immuno-Oncology PreClinical Clinical Rights
Fate-NK100 – AML

Worldwide
Fate-NK100 – Ovarian

Worldwide
Fate-NK100 – Solid Tumor mAb Combo

Worldwide
FT500 (iNK Cell)1

Worldwide
FT516 (Engineered hnCD16 iNK Cell)1

Worldwide
FT538 (Engineered CD38- iNK Cell)1

Worldwide
FT819 (Engineered CAR19 iT Cell)1

Worldwide
Ex Vivo T-Cell Modulation Collaboration2

Milestone / Royalties
IMMUNO-REGULATION
ProTmune™ – Graft-versus-Host Disease

Worldwide
ToleraCyte™ – Autoimmune Disorders

Worldwide
FT300 (iMDS Cell)1

Worldwide
Immuno-Oncology Phase Rights
Fate-NK100 – AML Phase 1 Worldwide
Fate-NK100 – Ovarian Phase 1 Worldwide
Fate-NK100 – Solid Tumor mAb Combo Phase 1 Worldwide
FT500 (iNK Cell)1 Preclinical Worldwide
FT516 (Engineered hnCD16 iNK Cell)1 Preclinical Worldwide
FT538 (Engineered CD38- iNK Cell)1 Preclinical Worldwide
FT819 (Engineered CAR19 iT Cell)1 Preclinical Worldwide
Ex Vivo T-Cell Modulation Collaboration2 Preclinical Milestone / Royalties
IMMUNO-REGULATION
ProTmune™ – Graft-versus-Host Disease Phase 2 Worldwide
ToleraCyte™ – Autoimmune Disorders Preclinical Worldwide
FT300 (iMDS Cell)1 Preclinical Worldwide

1. Off-the-Shelf (OTS) using Clonal Master Induced Pluripotent Stem Cell (iPSC) Lines.

2. Collaboration excludes all cell types derived from induced pluripotent stem cells including engineered T cells.

Fate Therapeutics